Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Phase 3 Safety Trial For GTX-104 In aSAH Patients
Portfolio Pulse from Benzinga Newsdesk
Acasti Pharma has announced that WuXi Clinical will conduct the STRIVE-ON Phase 3 safety trial for GTX-104 in aSAH patients. The trial aims to evaluate the safety and tolerability of GTX-104 compared to oral nimodipine.
July 10, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acasti Pharma's partnership with WuXi Clinical for the Phase 3 trial of GTX-104 could potentially impact the company's stock positively if the trial results are favorable.
The announcement of a new Phase 3 trial is a significant event for a biotech company like Acasti Pharma. If the trial results are positive, it could lead to regulatory approval and potential revenue from the drug, which would likely have a positive impact on the company's stock. However, the outcome of the trial is uncertain, hence the confidence score is not at the maximum.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100